Response Predictive Factors of Basal Cell Carcinoma to Treatment with a Mixture of Interferons
Keywords:
, carcinoma basocelular, interferon alfa, interferon gamma, factores predictivos, respuesta clínica AbstractAbstract
Introduction: For basal cell carcinoma there are therapeutic protocols whose choice depends on the risk factors. HeberFERON was incorporated into the Cuban standards for this variant of skin cancer, however, its indication is not stratified.
Objective: To identify the response predictive factors to this treatment option.
Methods: A descriptive and longitudinal study was carried out at Dr. Carlos J. Finlay Polyclinic in the period from January 2017 to December 2023. The sample consisted of 126 patients with single or multiple lesions, who met the inclusion and exclusion criteria. The study variables were age, sex, history of skin cancer, skin phototype, presence of arterial hypertension, tumor type, histological subtype, evolution time, largest diameter and clinical response to treatment. Univariate analysis was performed using absolute and relative frequencies and the contingency coefficient. Multivariate analysis was based on a classification and regression tree.
Results: Out of the epidemiological variables, age and arterial hypertension were found to be moderately associated with response. Histological subtype, tumor size and evolution time were the clinical and histological variables with the greatest association with response. The classification tree allowed a preliminary stratification into high, intermediate and low risk with good predictive capacity.
Conclusions: The age of the patients, the evolution time and the tumor size were the predictive factors of the response to HeberFERON in basal cell carcinoma.
Keywords: basal cell carcinoma; interferon alpha; interferon gamma; predictive factors; clinical response.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Meilyn Fernández Martori, Silvio Faustino Soler Cárdenas, Jorge Bacallao Gallestey
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.
You are free to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform and build upon the material
- The license cannot revoke these freedoms as long as you follow the terms of the license.
Under the following terms:
- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.
- Non-Commercial Purpose- You may not make use of the material for commercial purposes.
- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
